Clinical trial
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
NCT00378508 · Yale University, Other · Completed
Key facts
| NCT number | NCT00378508 |
|---|---|
| Title | Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes |
| Official title | Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes |
| Lead sponsor | Yale University, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH Juvenile Diabetes Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm |
| Enrollment | 63 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2013 |
| First posted | Sep 20, 2006 |
| Last update posted | Aug 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: